Expertise in
11
conditions

Dr. Christine E. Codding

Rheumatology
Christine E Codding MD PC
1211 N Shartel Ave, Suite 700, 
Oklahoma City, OK 
Accepting New Patients
Expertise in
11
conditions
Christine E Codding MD PC
1211 N Shartel Ave, Suite 700, 
Oklahoma City, OK 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christine Codding is a Rheumatologist in Oklahoma City, Oklahoma. Dr. Codding is highly rated in 11 conditions, according to our data. Her top areas of expertise are Rheumatoid Arthritis (RA), Palindromic Rheumatism, Psoriatic Arthritis, and Ankylosing Spondylitis. Dr. Codding is currently accepting new patients.

Her clinical research consists of co-authoring 7 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in OK
Hospital Affiliations
Norman Regional
Community Hospital, LLC
Ssm Health St Anthony Hospital - Oklahoma City
Ssm Health St Anthony Hospital - Shawnee
Integris Southwest Medical Center
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
CommunityCare
  • HMO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

CHRISTINE E CODDING MD PC
1211 N Shartel Ave, Suite 700, Oklahoma City, OK 73103
Other Locations
ABSENTEE SHAWNEE TRIBAL HEALTH AUTHORITY, INC
15951 Little Axe Dr, Norman, OK 73026

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study
Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Procedure, Device, Drug
Study Drug: Conventional Synthetic DMARD
Study Phase: Phase 3
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis
A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 12, 2023
Intervention Type: Drug
Study Drug: LY3462817
Study Phase: Phase 2
View 6 Less Clinical Trials

7 Total Publications

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study.
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study.
Journal: Rheumatology and therapy
Published: April 03, 2019
Similar Doctors
Expertise in
4
conditions
Dr. Joan T. Merrill
Rheumatology
Expertise in
4
conditions
Dr. Joan T. Merrill
Rheumatology
825 Ne 13th St, Omrf E110, 
Oklahoma City, OK 
 (1.6 miles away)
405-271-7805
Languages Spoken:
English

Joan Merrill is a Rheumatologist in Oklahoma City, Oklahoma. Dr. Merrill is highly rated in 4 conditions, according to our data. Her top areas of expertise are Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Arthritis, and Cutaneous Lupus Erythematosus (CLE).

Expertise in
6
conditions
Dr. Ira N. Targoff
Rheumatology | Allergy and Immunology
Expertise in
6
conditions
Dr. Ira N. Targoff
Rheumatology | Allergy and Immunology

Ou Health Partners Inc

900 Ne 10th St, Ouhp Family Medicine, 
Oklahoma City, OK 
 (1.6 miles away)
405-271-4311
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ira Targoff is a Rheumatologist and an Allergy and Immunologist in Oklahoma City, Oklahoma. Dr. Targoff is highly rated in 6 conditions, according to our data. His top areas of expertise are Dermatomyositis, Juvenile Dermatomyositis, Polymyositis, and Myositis. Dr. Targoff is currently accepting new patients.

Expertise in
29
conditions
Dr. Fahed F. Hamadeh
Rheumatology
Expertise in
29
conditions
Dr. Fahed F. Hamadeh
Rheumatology

Saints Medical Group, LLC

1000 N Lee Ave, 
Oklahoma City, OK 
 (0.2 miles away)
405-272-7000
Languages Spoken:
English, Arabic, Farsi
See accepted insurances
Accepting New Patients
Offers Telehealth

Fahed Hamadeh is a Rheumatologist in Oklahoma City, Oklahoma. Dr. Hamadeh is highly rated in 29 conditions, according to our data. His top areas of expertise are Microscopic Polyangiitis, Psoriatic Arthritis, Rheumatoid Arthritis (RA), and Psoriasis. Dr. Hamadeh is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Codding's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile